MedPath

Sustained Inflation and Chest Compression Versus 3:1 Chest Compression to Ventilation Ratio During Cardiopulmonary Resuscitation of Asphyxiated Newborns - a Multi-centre, International Cluster Randomized Control Trial

Not Applicable
Not yet recruiting
Conditions
Cardiac Arrest
Registration Number
NCT06577818
Lead Sponsor
University of Alberta
Brief Summary

Newborn infants who require cardiopulmonary resuscitation at birth receive chest compression using a 3-Compression to 1-Ventilation (3:1 C:V) ratio. However, the optimal chest compression technique during cardiopulmonary resuscitation is uncertain and identified as a critical gap in evidence. The International Consensus Statement advises to use the 3:1 C:V ratio based on animal studies, and states that there are no clinical trials to support this approach and called for more research. There continues to be uncertainty about the optimal chest compression technique during cardiopulmonary resuscitation.

This trial will compare if in newborn infants with cardiac arrest in the delivery room does providing CC+SI (a new chest compression technique) compared to 3:1 C:V decreases the incidence of mortality at hospital discharge.

This will be a multi-centre international cluster randomized trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
554
Inclusion Criteria

i) Newborns with gestational age born between 28 to 43 weeks based on best available obstetrical estimate; ii) Newborns designated to receive full resuscitation, i.e., parental request or pre-determined decision to provide only comfort care at birth; iii) No known major congenital or chromosomal malformation. All newborns who meet inclusion criteria will be enrolled as the centres agreed to change their local hospital policy during the trial. The inclusion criteria are designed to be pragmatic and provide useful knowledge translation for most of the patient population in the future.

Exclusion Criteria

i) Newborns born outside of study centers and transported to centers after delivery. Sex, race, and ethnicity are not part of the exclusion criteria for this trial, and as such it should represent the combined demographics of all centers involved.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Neonatal mortality0-40 days after birth

Death which occurs until first discharge from Hospital

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Royal Alexandra Hospital

🇨🇦

Edmonton, Canada

Royal Alexandra Hospital
🇨🇦Edmonton, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.